乳腺癌是全球女性最为常见的恶性肿瘤。2022 年，全球乳腺癌新发病例达 230 万例，死亡 67 万例[1]。同年，中国乳腺癌新发病例约 35.7 万例，死亡病例约 7.5 万例[2]，严重威胁女性健康。HER2 是乳腺癌中的重要治疗靶点，抗 ...

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." ...

乳腺癌是目前全球癌症发病率最高的疾病，大概3%到8%的乳腺癌患者确诊的时候会出现转移，大概30%的早期乳腺癌会最后发展成为无法治愈的晚期乳腺癌，晚期乳腺癌的5年生存率仅为27%。对于乳腺癌的治疗来说，第一步就是确定是那种类型的乳腺癌。通过对激素受体E ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...